Also of interest in this age group is the impact of prophylactic HPV vaccination on HPV incidence. Prophylactic HPV vaccines have been widely available in the United State since 2006, and are recommended for 11-to -12 year olds (with "catch-up" vaccination through age 26). 4 While data from the National Health and Nutrition Examination Survey (NHANES) indicate that vaccination has reduced vaccine-type HPV prevalence in adolescent and young adult females, 5 data on the impact of HPV vaccination on HPV incidence in real-world cohorts are limited.
From 2010-2012, we recruited and followed a cohort of 18-to 24-year-old female online daters in a longitudinal study of HPV infections. "Online dating" was defined as using the internet to search for romantic partners, regardless of whether the result was meeting a sex partner. Study aims were to determine risk factors for HPV infection associated with online dating and other sexual behaviors, as well as to estimate the protective effect of HPV vaccination in a real-world cohort of young women actively seeking new partners. Furthermore, we sought to compare rates of and risk factors for HPV infections to those observed in a previous cohort of mid-adult (25-to 65-year-old) female online daters that we recruited and followed with a similar protocol. In our mid-adult cohort, associations between online dating and HPV infection were inconsistent, with an increased likelihood of prevalent infection associated with online dating, 6 but no association for incident HPV. 7 We previously reported no association between online dating and prevalent HPV infection in a cross-sectional analysis of young adult female online daters, but did report a protective effect of selfreporting ≥1 dose of HPV vaccine on prevalent vaccine-type HPV. 8 In this paper, we report results from a subset of young female online daters that were followed longitudinally, including HPV incidence and associated risk and protective factors.
| MATERIALS AND METHODS
From October 2010 to May 2012, we enrolled 18-to 24-year-old female online daters into a longitudinal study of HPV infections.
Women were recruited through advertisements posted on Craigslist.
org and other free volunteer posting Web sites (described previously in our parallel study of 25-to 65-year-old online daters 6 ). Eligibility screening for all potential subjects was conducted by telephone. To be eligible, women had to report using the internet within the previous 12 months to search for partners. Women were excluded if they were pregnant, breastfeeding, or planning a pregnancy within the next 6 months, were hysterectomized, were immunocompromised, or reported no history of sex with men. Consent forms were mailed to eligible women, and women were enrolled after returning the signed consent form. The protocol for the study was reviewed and approved by the University of Washington Institutional Review Board.
Participants received up to four mailings at 4-month intervals with a kit for self-collecting vaginal samples for HPV DNA testing 6 and a survey with questions on demographics, sexual behavior, and health history (including HPV vaccination status). Vaginal samples were tested for HPV DNA using polymerase chain reaction (PCR)-based methods described previously. 6 HPV L1 consensus primers MY09, MY11, and HMB01 and β-globin primers PC04 and GH2 were used to simultaneously amplify HPV DNA and β-globin. behavior variables that were statistically significant at the P < 0.10 level in univariate analyses. Similar methods were used to evaluate the association between HPV vaccination history (≥1 vs 0 doses) and incident HPV infection with vaccine types (6, 11, 16, or 18 Fifty-eight percent reported new or multiple male sex partners within 6 months of enrollment, and 36% self-reported a history of prophylactic HPV vaccination (Table 1) . Mean follow-up duration (±SD) was 12.6 (±3.4) months, the mean interval between sample collections was 5.3 (±2.0) months, and 108 women (66%) returned four samples.
The incidence rate of clinically relevant HPV was 36.9 per 100
women-years, with a 12-month cumulative incidence of 32.9%
(26.0-41.0%) ( Table 2 and Figure 1 ). The individual types with the highest incidence rates were HPV-56, HPV-53, and HPV-52. The incidence rate of detecting any new vaccine-type HPV was 7.2 per 100
women years with a 12-month cumulative incidence of 8.1%
(4.7-13.9%). A total of 100 incident clinically relevant HPV infections were detected during follow-up, including 64 that were detected prior to the last follow-up visit. Of these 64, 43 (67.2%) were re-detected at the subsequent follow-up visit.
In univariate analyses, lifetime number of male sex partners and recent sex with male partners were each positively associated with an increased likelihood of incident infections with clinically relevant HPV types (Table 3 ). In analyses restricted to women reporting male partners in the past 6 months, reporting multiple sex partners and new sex partners were each associated with an increased likelihood of infection. We then created a composite variable measuring report of recent new and/or multiple male sex partners; women with at least one of these risk factors had a higher likelihood of infection than women who were not recently sexually active. Univariate results were similar in models using oncogenic HPV as the outcome (data not shown).
The multivariate analysis included the composite recent sexual behavior variable and the lifetime number of partners variable ( For analyses restricted to vaccine-type HPV, history of HPV vaccination was inversely associated with incident infection (Table 4) . 
| DISCUSSION
In this study, we followed a cohort of young adult female online daters would have been vaccinated under "catch up" recommendations for females 13 years of age and older. 4 Nonetheless, using the baseline data from this high-risk young adult cohort, we previously reported a statistically significant 61% reduction in vaccine-type HPV prevalence for self-reporting ≥1 versus no doses of HPV vaccine. 8 self-reported history HPV vaccination (≥1 dose) was associated with a reduction in vaccine-type HPV prevalence (16, 18, 6, 11) of 89%. 5 In a recent longitudinal study of sexually active adolescent females (aged 13-21 years) in a U.S. inner city, there was a 78% reduction in quadrivalent vaccine-type HPV incidence associated with being fully vaccinated versus unvaccinated. 16 We also note that the incidence of vaccine-type HPV in our partially vaccinated cohort was lower than in 15-to 25-year-old women enrolled in the placebo arms of HPV vaccine trials. For example, whereas the incidence of HPV-16 was 4.4 per 100
person-years in our study, placebo-arm incidence of HPV-16 was 5.9
per 100 person-years in the quadrivalent vaccine trial 17 and 5.0 per 100 person-years in the bivalent vaccine trial. 18 We did not find evidence that sex with partners met online, per se, increases the risk of HPV infection for young women. While reporting recent new or multiple male sex partners was associated with increased infection risk (similar to results in our mid-adult cohort 7 ), Restricted to women 21 years or older at the first visit. f Coded "no" if self-reported no history of HPV vaccination and "yes" if self-reported at least 1 dose HPV vaccine. g Restricted to women reporting a male sex partner in the past 6 months. h The variable was coded as "always" if the subject reported always using condoms with all male partners during the past 6 months. If a subject reported not always using condoms with at least one male partner, the variable was coded as "not always." Otherwise, if condom use data were missing for at least one partner, the variable was set to missing. Vaccine-type HPV (6, 11, 16, and 18) . b The 164 women contributed an observation for each vaccine-type for which they tested negative at baseline, or N = 635 women-types. Women-types could change categories throughout follow-up for time-dependent variables; therefore the number of women-types at risk (n) may exceed total N for timedependent variable.
c Coded "no" if self-reported no history of HPV vaccination and "yes" if self-reported at least 1 dose HPV vaccine. d The multivariate model was adjusted for lifetime number of male sex partners at baseline and a composite sexual behavior variable reflecting sexual behavior in the past 6 months: no male sex partner, one non-new partner, new and/or multiple male partners. Due to some zero-cells, we used Firth's penalized likelihood logistic regression to estimate the odds ratio. To account for within-subject correlation, we permuted HPV vaccine status across women (1000 permutations) to evaluate the P-value. The P-values from the Firth model and the permuted distribution were 0.148 and 0.143, respectively.
whether or not a partner was met online was unassociated. Similarly, in our previous analysis of the baseline data from this cohort, meeting partners online was not associated with prevalent oncogenic HPV. 8 Furthermore, in our previous study of 25-to 65-year-old women, online dating was associated with prevalent but not incident HPV. 6, 7 Other studies on the associations between online sex partner seeking and STI risk have been equivocal. [19] [20] [21] As we noted previously, 8 
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